Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-08
2008-01-08
Shiao, Rei-tsang (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S022000
Reexamination Certificate
active
10864857
ABSTRACT:
Chelants and macrocyclic metal complexes thereof, methods of preparing the chelants and macrocyclic metal complexes, and radiopharmaceutical compositions comprising the macrocyclic metal complexes are disclosed. Methods of using the macrocyclic metal complexes as radiopharmaceuticals for the diagnosis of cardiovascular disorders, infectious diseases and cancer are also disclosed. Chelants as bifunctional chelators (BFCs) for the radiolabeling of target-specific biomolecules, such as proteins, peptides, peptidomimetics, non-peptide receptor ligands, enzyme inhibitors, and enzyme substrates are disclosed. Methods of using macrocyclic metal complexes containing the chelant-biomolecule conjugates as target-specific diagnostic radiopharmaceuticals that selectively localize at sites of disease and allow an image to be obtained of the loci using gamma scintigraphy are disclosed. Methods of use of the radiopharmaceuticals as imaging agents for the diagnosis of cardiovascular disorders, such as thromboembolic disease or atherosclerosis, infectious disease and cancer are further disclosed.
REFERENCES:
patent: 4427646 (1984-01-01), Olexa et al.
patent: 4578079 (1986-03-01), Ruoslahti et al.
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 5086069 (1992-02-01), Klein et al.
patent: 5206370 (1993-04-01), Schwartz et al.
patent: 5217705 (1993-06-01), Reno et al.
patent: 5270030 (1993-12-01), Vogel et al.
patent: 5277892 (1994-01-01), Rhodes
patent: 5279812 (1994-01-01), Krstenansky et al.
patent: 5350837 (1994-09-01), Bridger et al.
patent: 5744120 (1998-04-01), Edwards et al.
patent: 5750088 (1998-05-01), Sworin et al.
patent: 5753520 (1998-05-01), Schwartz et al.
patent: 5776894 (1998-07-01), Albert et al.
patent: 5792444 (1998-08-01), Fischman et al.
patent: 5871711 (1999-02-01), Dean et al.
patent: 5879659 (1999-03-01), Edwards et al.
patent: 6015904 (2000-01-01), Sworin et al.
patent: 6022523 (2000-02-01), DeGrado et al.
patent: 6251364 (2001-06-01), Liu
patent: 6329513 (2001-12-01), Archer et al.
patent: 0 410 537 (1991-01-01), None
patent: 0 410 539 (1991-01-01), None
patent: 0 410 541 (1991-01-01), None
patent: 0 422 937 (1994-03-01), None
patent: 0 422 938 (1995-02-01), None
patent: 0 398 143 (1995-03-01), None
patent: 0 478 328 (1996-01-01), None
patent: 0 425 212 (1999-04-01), None
patent: 2268494 (1994-01-01), None
patent: WO89/05150 (1989-06-01), None
patent: WO89/10135 (1989-11-01), None
patent: WO90/03391 (1990-04-01), None
patent: WO90/15818 (1990-12-01), None
patent: WO91/01331 (1991-02-01), None
patent: WO91/15515 (1991-10-01), None
patent: WO92/13572 (1992-08-01), None
patent: WO93/12819 (1993-07-01), None
patent: WO93/17719 (1993-09-01), None
patent: WO93/17719 (1993-09-01), None
patent: WO93/23085 (1993-11-01), None
patent: WO94/05269 (1994-03-01), None
patent: WO 00/00178 (2000-06-01), None
Baumgartner, H.R., “Eine neue methode zur erzeugung von thrombin durch gezielte Überdehnung der gefäβwand,”Z. Ges. Exp. Med., 1963, 137, 227-247 (see page 243 for the English Summary).
Dewanjee, M.K., “The chemistry of99mTc-labeled radiopharmaceuticals,”Semin. In Nucl. Med., 1990, 20(1), 5-27.
Dilworth, J.R., et al., “The biomedical chemistry of technetium and rhenium,”Chem. Soc. Rev., 1998, 27, 43-55.
Edwards, D.S., et al., “New and versatile ternary ligand system for technetium radiopharmaceuticals: water soluble phosphines and tricine as coligands in labeling a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with99mTc,”Bioconjugate Chem., 1997, 8, 146-154.
Edwards, S.D., et al., “RP463: a stabilized technetium-99m complex of a hydrazine nicotinamide derivatized chemotactic peptide for infection imaging,”Bioconjugate Chem., 1999, 10, 884-891.
Edwards, S.D., et al., “99mTc-labeling of hydrazones of a nydrazinonicotinamide conjugated cyclic peptide,”Bioconjugate Chem., 1999, 10, 803-807.
Elmaleh, SD.R., et al., “Rapid noninvasive detection of experimental atherosclerotic lesions with novel99mTc-labeled diadenosine tetraphosphates,”Proc. Natl. Sci. USA, 1998, 95, 691-695.
Fischman, A.J., et al., “Infection imaging with technetium-99m-labeled chemotactic peptide analogs,”Semin. Nuc. Med., 1994, 24(2), 154-168.
Fritzberg, A.R., et al., “Approaches to radiolabeling of antibodies for diagnosis and therapy of cancer,”Pharmaceutical Res., 1988, 5(6), 325-334.
Griffiths, G.L., et al., “Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium,”Bioconj. Chem., 1992, 3(2), 91-99.
Harris, T.D., et al., “Synthesis of stable hydrazones of a hydrazinonicotinyl-modified peptide for the preparation of99mTc-labeled radiopharmaceuticals,”Bioconjugate Chem., 1999, 10, 808-814.
Hartman, G.D., et al., “Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors,”J. Med. Chem., 1992, 35, 4640-4642.
Hom, R.K., et al., “Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: recent developments and encouraging results,”Nucl. Med. &Biol., 1997, 24, 485-498.
Jurisson, S., et al., “Coordination compounds in nuclear medicine,”Chem. Rev., 1993, 93, 1137-1156.
Jurisson, S.S., et al., “Potential technetium small molecule radiopharmaceuticals,”Chem. Rev., 1999, 99, 2205-2218.
Larsen, S.K., et al., “[99mTc]Tricine: a useful precursor complex for the radiolabeling of hydrazinonicotinate protein conjugates,”Bioconjugate Chem., 1995, 6, 635-638.
Liu, S., et al., “Labeling a hydrazine nicotinamide-modified cyclic IIb/IIIa receptor antagonist with99mTc using aminocarboxylates as coligands,”Bioconjugate Chem., 1996, 7, 63-71.
Liu, S., et al., “99mTc labeling of highly potent small peptides,”Bioconjugate Chem., 1997, 8, 621-636.
Liu, S., et al., “A novel ternary ligand system for99mTC-labeling of hydrazine nicotinamide-modified biologically active molecules using imine-N-containing heterocycles as coligands,”Bioconjugate Chem., 1998, 9, 583-595.
Liu, S., et al., “Radio-LC-MS for the characterization of99mTc-labeled bioconjugates,”Bioconjugate Chem., 2000, 11, 113-117.
Liu, S., et al., “Technetium complexes of a hydrazinonicotinamide-conjugated cyclic peptide and 2-hydrazinopyridine: synthesis and characterization,”Inorg. Chem., 1999, 38(6), 1326-1335.
Liu, S., et al, “99mTc-labeled small peptides as diagnostic radiopharmaceuticals,”Chem. Rev., 1999, 99, 2235-2268.
Liu, S., et al., “Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals,”Bioconjugate Chem., 2001, 12, 7-34.
Narula, J., et al., “Noninvasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F(ab')2specific for the proliferating smooth muscle cells of human atheroma,”Circulation, 1995, 92, 474-484.
Naurla, J., et al., “Gamma imaging of atherosclerotid lesions: the role of antibody affinity in in vivo target localization,”J. Nucl. Cardiol., 1996, 3, 231-241.
Ojima, D., et al., “Design and synthesis of new RGD peptides as inhibitors of human platelet aggregation,”204thMeeting of the Am. Chem. Soc., 1992, Abstract 44, 1 page.
Remington's Pharmaceutical Sciences,17thEd., Mack Publishing Co., 1985, p. 1418.
Roberts, D.C., et al., “Unusual amino acids in peptide synthesis,”The Peptides, 1983, 5(6), 341-449.
Yuanfang, L., et al., “Radiolabeling of monoclonal antibodies with metal chelates,”Pure&Appl. Chem., 1991, 63, 427-463.
U.S. Appl. No. 10/864,792, filed Jun. 9, 2004, Liu.
Bristol-Myers Squibb Pharma Company
Chapman Jennifer C.
Levis John F.
Shiao Rei-tsang
Woodcock Wasburn LLP
LandOfFree
Chelants and macrocyclic metal complex radiopharmaceuticals... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chelants and macrocyclic metal complex radiopharmaceuticals..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chelants and macrocyclic metal complex radiopharmaceuticals... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3915427